Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

36.4%

4 terminated/withdrawn out of 11 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

1 recruiting6 with results

Enrollment Performance

Analytics

Phase 1
5(45.5%)
Phase 2
4(36.4%)
Early Phase 1
2(18.2%)
11Total
Phase 1(5)
Phase 2(4)
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT05343481Phase 2Completed

Efficacy of VTP-300 in Chronic Hepatitis B Infection

Role: lead

NCT06310291Early Phase 1Recruiting

VTP-1000 in Adults With Celiac Disease

Role: lead

NCT05617040Phase 1Terminated

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Role: lead

NCT04607850Phase 1Completed

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

Role: lead

NCT04297917Phase 1Completed

First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection

Role: lead

NCT03815942Phase 1Terminated

VAccination in Early and ADvanced Prostate caNCEr

Role: collaborator

NCT04778904Phase 1Completed

First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

Role: lead

NCT03880474Phase 2Terminated

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

Role: lead

NCT03883113Phase 2Completed

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Role: lead

NCT03300362Phase 2Terminated

Improved Novel VaccIne CombinaTion InflUenza Study

Role: lead

NCT03277456Early Phase 1Completed

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

Role: lead

All 11 trials loaded